Trial Profile
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; SEA CD40 (Primary) ; SEA CD40 (Primary)
- Indications Adenocarcinoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Lymphoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seagen
- 27 Apr 2023 Status changed from active, no longer recruiting to discontinued.
- 21 Jan 2023 Updated Results( As of August 16, 2022, n=61) assessing safety and tolerability of gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma presented at the 2023 Gastrointestinal Cancers Symposium
- 16 Dec 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Jan 2024.